Elizabeth Haglind, MD
Endocrinology, Diabetes & Metabolism · Edina, MNNPI 1720186042
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,232 of the $2,931 with a category attached, or 76.1%. It is spread thinly across 36 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $762 and has fallen 59.5% since, to $309 in 2025.
Across 130 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Senseonics, Incorporated$657
- Medtronic$264
- Amgen$219
- Dexcom, Inc.$167
- Abbott$123
- Mannkind Corporation$119
- plus $1K from 30 others
What the payments were for
- Speaking & faculty fees$64022%
- Food & beverage$2,23276%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Senseonics, Incorporated | 3 | $657 |
| Medtronic(2 entities) | 14 | $264 |
| Amgen(2 entities) | 14 | $219 |
| Dexcom, Inc. | 6 | $167 |
| Abbott | 7 | $123 |
| Mannkind Corporation | 4 | $119 |
| Ipsen Biopharmaceuticals, Inc | 4 | $113 |
| Insulet Corporation | 5 | $105 |
| Boehringer Ingelheim | 6 | $100 |
| BETA Bionics, Inc. | 7 | $97 |
| Novartis | 6 | $97 |
| Antares Pharma, Inc. | 6 | $82 |
| Valeritas, Inc. | 2 | $77 |
| AstraZeneca(2 entities) | 5 | $65 |
| Novo Nordisk | 5 | $63 |
| Esperion Therapeutics, Inc. | 4 | $57 |
| Radius Health, Inc. | 4 | $56 |
| Tandem Diabetes Care, Inc. | 3 | $51 |
| Corcept Therapeutics | 2 | $48 |
| Intuity Medical Inc | 3 | $47 |
| Recordati_rare_diseases_inc. | 2 | $40 |
| Merck | 3 | $37 |
| Cequr Corporation | 1 | $30 |
| Companion Medical, Inc. | 2 | $22 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Pfizer | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Bayer | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Eversense$640
How this compares
$2,931 in reported general payments places this provider in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 145 | $251,164 |
| Teriparatide | 58 | $149,719 |
| TrulicityDulaglutide | 76 | $109,671 |
| MounjaroTirzepatide | 72 | $96,897 |
| JardianceEmpagliflozin | 43 | $73,154 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 66 | $65,024 |
| TymlosAbaloparatide | 22 | $59,667 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $21,352 |
| FarxigaDapagliflozin Propanediol | 26 | $17,571 |
| Victoza 3-PakLiraglutide | 14 | $14,250 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $12,018 |
| SynthroidLevothyroxine Sodium | 111 | $11,817 |
| Levothyroxine Sodium | 650 | $10,532 |
| HumalogInsulin Lispro | 33 | $9,807 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $9,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $63 | $256,687164 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $16 | $218,135193 claims |
| Boehringer IngelheimJardiance | $100 | $73,15443 claims |
| Radius Health, Inc.Tymlos | $56 | $59,66722 claims |
| AstraZenecaFarxiga | $65 | $17,57126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Edina
- Thomas LaedtkeEdina$39K
- John ChowEdina$3K
- Sarah Bou MalhamEdina$549
- Richard BergenstalSt Louis Park$595K
- Farha KhanCoon Rapids$349K
- Mark HolmSaint Cloud$318K
- Marjorie Ann MalbasRochester$222K
- Anders CarlsonSt Louis Park$163K
- Maria CaramoriMinneapolis$147K
- Irina BancosRochester$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.